TDP-43 pathology is associated with divergent protein profiles in ALS brain and spinal cord

Abstract Neuronal and glial cytoplasmic inclusions positive for TAR DNA-binding protein 43 (TDP-43) are the defining pathological hallmark of 97% of amyotrophic lateral sclerosis (ALS) and 50% of frontotemporal dementia (FTD). The ALS-FTD clinicopathological spectrum variably involves cortical and s...

Full description

Bibliographic Details
Published in:	Acta Neuropathologica Communications
Main Authors:	Emily Feneberg, Alexander G. Thompson, Philip D. Charles, Iolanda Vendrell, Benedikt M. Kessler, Roman Fischer, Olaf Ansorge, Elizabeth Gray, Kevin Talbot, Martin R. Turner
Format:	Article
Language:	English
Published:	BMC 2025-08-01
Subjects:	TDP-43 Amyotrophic lateral sclerosis Proteomics Tissue Brain Spinal cord
Online Access:	https://doi.org/10.1186/s40478-025-02084-y

Similar Items

TDP-43 Proteinopathy Specific Biomarker Development
by: Isabell Cordts, et al.
Published: (2023-02-01)

TDP-43 pathology is sufficient to drive axon initial segment plasticity and hyperexcitability of spinal motoneurones in vivo in the TDP43-ΔNLS model of Amyotrophic Lateral Sclerosis
by: Svetlana Djukic, et al.
Published: (2025-02-01)

Progranulin reduces insoluble TDP-43 levels, slows down axonal degeneration and prolongs survival in mutant TDP-43 mice
by: Sander Beel, et al.
Published: (2018-10-01)

Low T-cell reactivity to TDP-43 peptides in ALS
by: Swetha Ramachandran, et al.
Published: (2023-07-01)

Cytoplasmic Human TDP-43 Mislocalization Induces Widespread Dendritic Spine Loss in Mouse Upper Motor Neurons
by: Marcus S. Dyer, et al.
Published: (2021-06-01)

c-Abl Regulates the Pathological Deposition of TDP-43 via Tyrosine 43 Phosphorylation
by: Saebom Lee, et al.
Published: (2022-12-01)

Advancements in TDP-43 research: Towards biomarkers and therapeutic targets for amyotrophic lateral sclerosis
by: Yuhan Wu, et al.
Published: (2025-03-01)

TDP-43 Cytoplasmic Translocation in the Skin Fibroblasts of ALS Patients
by: Miguel A. Rubio, et al.
Published: (2022-01-01)

Liquid–Liquid Phase Separation Enhances TDP-43 LCD Aggregation but Delays Seeded Aggregation
by: Donya Pakravan, et al.
Published: (2021-04-01)

Validation of a newly developed immunoassay for TDP-43 in human plasma
by: Sayo Matsuura, et al.
Published: (2024-01-01)

Cyclin F can alter the turnover of TDP-43
by: Stephanie L. Rayner, et al.
Published: (2024-03-01)

Heterogeneity of cortical pTDP-43 inclusion morphologies in amyotrophic lateral sclerosis
by: Rachel H. Tan, et al.
Published: (2023-11-01)

The effect of pH alterations on TDP-43 in a cellular model of amyotrophic lateral sclerosis
by: Yara Al Ojaimi, et al.
Published: (2024-07-01)

Identification of Genetic Modifiers of TDP-43: Inflammatory Activation of Astrocytes for Neuroinflammation
by: Jae-Hong Kim, et al.
Published: (2021-03-01)

ALS-linked mutant TDP-43 in oligodendrocytes induces oligodendrocyte damage and exacerbates motor dysfunction in mice
by: Mai Horiuchi, et al.
Published: (2024-11-01)

Suppression of Conditional TDP-43 Transgene Expression Differentially Affects Early Cognitive and Social Phenotypes in TDP-43 Mice
by: Pablo R. Silva, et al.
Published: (2019-04-01)

TDP-43 mislocalization drives neurofilament changes in a novel model of TDP-43 proteinopathy
by: Rachel Atkinson, et al.
Published: (2021-02-01)

TDP-43-mediated amyotrophic lateral sclerosis: new/hidden insights from Drosophila
by: Davide Colaianni, et al.
Published: (2025-10-01)

TDP-43 dysfunction leads to bioenergetic failure and lipid metabolic rewiring in human cells
by: Miriam Ceron-Codorniu, et al.
Published: (2024-09-01)

TDP-43 and HERV-K Envelope-Specific Immunogenic Epitopes Are Recognized in ALS Patients
by: Elena Rita Simula, et al.
Published: (2021-11-01)

Both cytoplasmic and nuclear accumulations of the protein are neurotoxic in Drosophila models of TDP-43 proteinopathies
by: Laetitia Miguel, et al.
Published: (2011-02-01)

A panel of TDP-43-regulated splicing events verifies loss of TDP-43 function in amyotrophic lateral sclerosis brain tissue
by: Maize C. Cao, et al.
Published: (2023-09-01)

Microglial CD68 and L-ferritin upregulation in response to phosphorylated-TDP-43 pathology in the amyotrophic lateral sclerosis brain
by: Molly E. V. Swanson, et al.
Published: (2023-04-01)

Altered TDP-43 Structure and Function: Key Insights into Aberrant RNA, Mitochondrial, and Cellular and Systemic Metabolism in Amyotrophic Lateral Sclerosis
by: Leanne Jiang, et al.
Published: (2022-07-01)

Molecular mechanisms and consequences of TDP-43 phosphorylation in neurodegeneration
by: Elise A. Kellett, et al.
Published: (2025-05-01)

CK1δ/ε kinases regulate TDP-43 phosphorylation and are therapeutic targets for ALS-related TDP-43 hyperphosphorylation
by: Vivian I. Ko, et al.
Published: (2024-06-01)

Alterations in stress granule dynamics driven by TDP-43 and FUS: A link to pathological inclusions in ALS?
by: Anais eAulas, et al.
Published: (2015-10-01)

TDP-43 as a potential biomarker for amyotrophic lateral sclerosis: a systematic review and meta-analysis
by: Vivek Majumder, et al.
Published: (2018-06-01)

Cytosolic calcium regulates cytoplasmic accumulation of TDP-43 through Calpain-A and Importin α3
by: Jeong Hyang Park, et al.
Published: (2020-12-01)

Neuronal TDP-43 aggregation drives changes in microglial morphology prior to immunophenotype in amyotrophic lateral sclerosis
by: Molly E. V. Swanson, et al.
Published: (2025-02-01)

The Pathobiology of TDP-43 C-Terminal Fragments in ALS and FTLD
by: Britt A. Berning, et al.
Published: (2019-04-01)

The Protective Effect of Edaravone on TDP-43 Plus Oxidative Stress-Induced Neurotoxicity in Neuronal Cells: Analysis of Its Neuroprotective Mechanisms Using RNA Sequencing
by: Aki Soejima-Kusunoki, et al.
Published: (2022-07-01)

TDP-43 overexpression in the hypothalamus drives neuropathology, dysregulates metabolism and impairs behavior in mice
by: Sofia Bergh, et al.
Published: (2025-05-01)

Dysregulation of SELENOI Is Associated with TDP-43 Neuropathology in Amyotrophic Lateral Sclerosis
by: Finula I. Isik, et al.
Published: (2025-09-01)

TDP-43 dysregulation and neuromuscular junction disruption in amyotrophic lateral sclerosis
by: Sarah Lépine, et al.
Published: (2022-12-01)

Protein aggregation and therapeutic strategies in SOD1- and TDP-43- linked ALS
by: Maria Tsekrekou, et al.
Published: (2024-05-01)

Patterns of synaptic loss in human amyotrophic lateral sclerosis spinal cord: a clinicopathological study
by: Oumayma Aousji, et al.
Published: (2023-07-01)

Targeting the glycine-rich domain of TDP-43 with antibodies prevents its aggregation in vitro and reduces neurofilament levels in vivo
by: Henrick Riemenschneider, et al.
Published: (2023-07-01)

Immunotherapy targeting the C-terminal domain of TDP-43 decreases neuropathology and confers neuroprotection in mouse models of ALS/FTD
by: Tariq Afroz, et al.
Published: (2023-04-01)

ALS monocyte-derived microglia-like cells reveal cytoplasmic TDP-43 accumulation, DNA damage, and cell-specific impairment of phagocytosis associated with disease progression
by: Hazel Quek, et al.
Published: (2022-02-01)